1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits

Merck & Co’s Marshall To Take Over

 
• By Andrew McConaghie

A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.

Novartis NIBR Cambridge, MA
Bradner has headed up the Cambridge, MA-headquartered NIBR since 2016, but will hand over to Fiona Marshall in November. • Source: Shutterstock

Jay Bradner is to leave Novartis after seven years as its leader of drug discovery, a departure which will add to a changing of the guard already underway at the Swiss-headquartered pharma company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.